

# Saamir A Hassan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4231315/publications.pdf>

Version: 2024-02-01

41  
papers

615  
citations

687363

13  
h-index

642732

23  
g-index

41  
all docs

41  
docs citations

41  
times ranked

833  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute coronary syndrome in patients with cancer. Expert Review of Cardiovascular Therapy, 2022, 20, 275-290.	1.5	4
2	Delayed bolus-tracking trigger at CT correlates with cardiac dysfunction and suboptimal portovenous contrast phase. Abdominal Radiology, 2021, 46, 826-835.	2.1	5
3	QT Prolongation in Cancer Patients. Frontiers in Cardiovascular Medicine, 2021, 8, 613625.	2.4	10
4	Rate of Progression of Aortic Stenosis in Patients With Cancer. Frontiers in Cardiovascular Medicine, 2021, 8, 644264.	2.4	2
5	Cardiac Magnetic Resonance Predicting Outcomes Among Patients at Risk for Cardiac AL Amyloidosis. Frontiers in Cardiovascular Medicine, 2021, 8, 626414.	2.4	8
6	Characteristics of infective endocarditis in a cancer population. Open Heart, 2021, 8, e001664.	2.3	7
7	Anemia in Cardiovascular Disease: Marker of Disease Severity or Disease-modifying Therapeutic Target?. Current Atherosclerosis Reports, 2021, 23, 61.	4.8	8
8	How to Perform Pericardiocentesis in Cancer Patients With Thrombocytopenia. JACC: CardioOncology, 2021, 3, 452-456.	4.0	5
9	Interventional Strategies in Cancer-induced Cardiovascular Disease. Current Oncology Reports, 2021, 23, 133.	4.0	2
10	Clinical Impact of Cardiovascular Magnetic Resonance in Cancer Patients With Suspected Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 734820.	2.4	2
11	Stress cardiomyopathy in hospitalized patients with cancer: machine learning analysis by primary malignancy type. ESC Heart Failure, 2021, , .	3.1	9
12	Cancer treatment resumption in patients with new-generation drug-eluting stents. Coronary Artery Disease, 2021, 32, 295-301.	0.7	8
13	State-of-the-art Review: Interventional Onco-Cardiology. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.9	3
14	Identifying Hemostatic Thresholds in Cancer Patients Undergoing Coronary Angiography Based on Platelet Count and Thromboelastography. Frontiers in Cardiovascular Medicine, 2020, 7, 9.	2.4	9
15	Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin. Cardio-Oncology, 2020, 6, 1.	1.7	22
16	Prevalence of pulmonary hypertension in myelofibrosis. Annals of Hematology, 2020, 99, 781-789.	1.8	9
17	Speckle-Tracking Echocardiography in Cardio-Oncology and Beyond. Texas Heart Institute Journal, 2020, 47, 96-107.	0.3	13
18	The 1, 2, 3, 4 of carcinoid heart disease: Comprehensive cardiovascular imaging is the mainstay of complex surgical treatment (Review). Oncology Letters, 2019, 17, 4126-4132.	1.8	4

#	ARTICLE	IF	CITATIONS
19	The Onco-cardiologist Dilemma: to Implant, to Defer, or to Avoid Transcatheter Aortic Valve Replacement in Cancer Patients with Aortic Stenosis?. <i>Current Cardiology Reports</i> , 2019, 21, 83.	2.9	11
20	Safety of Transesophageal Echocardiography in Patients with Thrombocytopenia. <i>Journal of the American Society of Echocardiography</i> , 2019, 32, 1010-1015.	2.8	8
21	Multimodality imaging in carcinoid heart disease. <i>Open Heart</i> , 2019, 6, e001060.	2.3	15
22	Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint Inhibitors. <i>American Journal of Cardiology</i> , 2019, 123, 1351-1357.	1.6	41
23	Carcinoid Heart Disease: a Comprehensive Review. <i>Current Cardiology Reports</i> , 2019, 21, 140.	2.9	11
24	Cardiac toxicities of anticancer treatments. <i>Current Opinion in Cardiology</i> , 2019, 34, 441-450.	1.8	16
25	Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib. <i>Cardiovascular Toxicology</i> , 2019, 19, 382-387.	2.7	17
26	Cardiovascular manifestations of Erdheim-Chester disease. <i>Echocardiography</i> , 2019, 36, 229-236.	0.9	24
27	Predictors of mortality following cardiac surgery for carcinoid heart disease.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15692-e15692.	1.6	0
28	Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis. <i>Current Atherosclerosis Reports</i> , 2018, 20, 10.	4.8	31
29	Evaluation and Management of Cardiac Tumors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 29.	0.9	58
30	Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosis. <i>Open Heart</i> , 2018, 5, e000881.	2.3	38
31	Echocardiographic measures associated with the presence of left ventricular thrombus in patients with chemotherapy-related cardiac dysfunction. <i>Echocardiography</i> , 2018, 35, 1512-1518.	0.9	4
32	Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 48.	2.4	13
33	Evolution of echocardiography in subclinical detection of cancer therapy-related cardiac dysfunction. <i>Echocardiography</i> , 2018, 35, 860-868.	0.9	9
34	Predictors of left ventricular systolic function recovery in the setting of sinus tachycardia in patients with cancer. <i>Echocardiography</i> , 2017, 34, 29-36.	0.9	0
35	Cancer as a Risk Factor for Cardiovascular Disease. <i>Current Oncology Reports</i> , 2017, 19, 39.	4.0	60
36	Carcinoid heart disease. <i>Heart</i> , 2017, 103, 1488-1495.	2.9	56

#	ARTICLE	IF	CITATIONS
37	Stress-Induced Cardiomyopathy in Cancer Patients. American Journal of Cardiology, 2017, 120, 2284-2288.	1.6	50
38	The role of cardiac MRI in cardio-oncology. Future Cardiology, 2017, 13, 311-316.	1.2	3
39	Improved reliability in left ventricular ejection fraction assessment by adopting quantitative methods. Echocardiography, 2016, 33, 1936-1937.	0.9	1
40	Withdrawal of Heart Failure Medications in Cancer Survivors With Chemotherapy-Induced Left Ventricular Dysfunction: A Pilot Study. Journal of Cardiac Failure, 2016, 22, 481-482.	1.7	2
41	Pericardial disease: a clinical review. Expert Review of Cardiovascular Therapy, 2016, 14, 525-539.	1.5	17